Atrial fibrillation in St Petersburg cohort: frequency, risk factors, antiarrhythmic therapy and thromboembolism prevention

Ионин, В. А.; Барашкова, Е. И.; Филатова, А. Г.; Баранова, Е. И.; Шляхто, Е. В.

doi:10.18705/1607-419x-2020-26-2-192-201

Cited by 11 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…По данным регистра GLORIA-AF, наиболее неблагоприятная ситуация с назначением антикоагулянтов в странах Азии, в частности, 41,8% пациентов в возрасте 65-74 лет и 45,9% пациентов 85 лет и старше не получали адекватной антитромботической терапии [52]. По данным когортного исследования, проведенного среди больных с ФП, обратившихся к кардиологам в Санкт-Петербурге, антикоагулянтная терапия (при наличии показаний) не была назначена 25,7% пациентов и, что имеет особое значение, 13,4% больных, перенесших инсульт или транзиторную ишемическую атаку, также не получали антикоагулянты [56].…”

Section: дислипидемияunclassified

Central directions for reducing cardiovascular mortality: what can be changed today?

Шляхто

Баранова

2020

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

The article provides modern data on the prevalence of cardiovascular diseases and mortality in Europe and Russia. Groups of high-risk patients requiring special attention when conducting measures to reduce cardiovascular mortality are discussed: patients with hypertension, including resistant, patients with severe dyslipidemia, heart failure, and atrial fibrillation. Particular attention is paid to the problem of effective and safe treatment and reducing cardiovascular mortality in patients with atrial fibrillation and a high risk of stroke. The treatment of these patients may be most successful due to the availability of effective medications that reduce cardiovascular mortality. The article outlines the major paradigms of modern healthcare: focus on results and patient, integration of inpatient and outpatient health care units and accelerating the innovation in the diagnosis and treatment of patients with cardiovascular diseases.

show abstract

Section: дислипидемияunclassified

Central directions for reducing cardiovascular mortality: what can be changed today?

Шляхто

Баранова

2020

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

show abstract

Patients with atrial fibrillation and a low risk of thromboembolic events: prescription rate of anticoagulant therapy according to a retrospective analysis

Druzhilov,

Kuznetsova

2023

Russ J Cardiol

View full text Add to dashboard Cite

Aim. To conduct a retrospective analysis of the prevalence of main risk factors for thromboembolic events (TEEs) and the prescription rate of anticoagulant therapy (ACT) in patients with atrial fibrillation (AF) and a low CHA2DS2-VASc score in certain Russian regions using artificial intelligence technologies.Material and methods. The information was obtained from the Webiomed predictive analytics platform. The sample included 87601 patients with AF aged 18-74 years (men, 49,5%, mean age, 59,3±12,3 years, mean CHA2DS2-VASc score, 2,3±1,5) who received care in medical organizations in 6 constituent entities of the Russian Federation in the period from 2016 to 2019. CHA2DS2VASc score of 1 and 2 in a man and a woman, respectively, was regarded as a moderate risk, while score of 0 and 1, respectively, as a low risk of TEEs.Results. There were 22337 (25,5%) patients with AF at moderate risk and 18366 (21,0%) patients at low risk of TEEs. With a moderate risk of TEEs, CHA2DS2-VASc score of 1 in 70,4% of cases was determined by hypertension, while in 15,7% — by age 65-74 years, in 9,0% — by heart failure, in 2,9% — by myocardial infarction and/or peripheral arterial disease, in 2,0% — by type 2 diabetes. In patients with AF and a moderate risk of TEEs, ACT was prescribed in 4927 (22,1%) patients, while with a low risk of TEEs — in 1833 (10,0%). Among patients with AF and a high risk of TEEs (n=46898, 53,5%), 1216 (24,6%) patients with ischemic stroke (IS) did not initially have a high CHA2DS2-VASc risk.Conclusion. In clinical practice, among patients with AF aged 18-74 years, there are quite often individuals with CHA2DS2-VASc score of 1 not associated with sex. These patients need an individualized approach in ACT, which is the basis for prospective studies in order to optimize the assessment of cardioembolic IS risk, as well as to analyze the efficacy and safety of long-term ACT.

show abstract

Changes in the prevalence of atrial fibrillation in the Russian population over a 13-year follow-up

Shapkina

Маздорова

Avdeeva

et al. 2022

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To study the prevalence of atrial fibrillation (AF) in the Russian urban population cohort aged 45-69 years and its changes over 13-year follow-up during aging.Material and methods. This cross-sectional long-term prospective study included random population sample of men and women 45-69 years (n=9360, HAPIEE project, Novosibirsk), which was examined in 2003-2005 and was re-examined twice and followed up for about 13±1,00 years in men and 13,1±2,17 years in women. The incidence of AF was assessed for individuals without AF or cardiovascular disease (CVD) at the baseline examination. Statistical analysis was performed using the SPSS software package (v.13.0).Results. In a population sample over a 13-year follow-up, AF prevalence increased from 1,6% (1,1% among women and 2,1% among men) at the age of 45-69 years to 4,2% (3,0% among women and 6,1% among men) aged 55-84 years according to screening rest ECG examinations. The prevalence of new AF cases over a 13-year followup in the cohort of 45-69 years old without previous CVD and AF was 5,6%, of which 40% were paroxysmal. The mean age at the time of first registered AF was 69±6,93 years, and was 2 years higher in women (70,0±6,83) than in men (68±6,93). The average period before the AF onset among people aged 45-69 years without baseline CVD and AF was 7,5±3,83 years for men and 8,1±4,02 years for women. The total prevalence of AF in the population sample was 8,3%. The highest AF prevalence was registered at the age of 65-69 years (11,4%) for men and 5 years later for women (12,0%) (p80 years decreased and amounted to 4,1% among men and 5,7% among women.Conclusion. In the Russian population sample (Novosibirsk) aged 45-69, the AF prevalence increased from 1,6 to 8,3% over 13 years of follow-up. In addition, 473 new AF cases were identified, ~40% of which were paroxysmal AF. The prevalence of AF in the Siberian population sample for the 45-60 years age group is comparable with the large Russian and North American studies, but higher for persons aged 60-74 years and lower for older age group, for both men and women.

show abstract

Atrial fibrillation in St Petersburg cohort: frequency, risk factors, antiarrhythmic therapy and thromboembolism prevention

Cited by 11 publications

References 14 publications

Central directions for reducing cardiovascular mortality: what can be changed today?

Central directions for reducing cardiovascular mortality: what can be changed today?

Patients with atrial fibrillation and a low risk of thromboembolic events: prescription rate of anticoagulant therapy according to a retrospective analysis

Changes in the prevalence of atrial fibrillation in the Russian population over a 13-year follow-up

Contact Info

Product

Resources

About